全球肿瘤精密医学市场估计价值为: 2024年1 300亿美元 预计将达到 到2031年达到3,640亿美元以复合年增长率增长 (CAGR)从2024年到2031年占8.9%. 精密肿瘤学侧重于针对每个患者特定基因、环境和生活方式的治疗和诊断。 这种方法分析了病人的基因化妆,并与现有的有针对性的疗法相匹配。

由于全球癌症发病率的上升以及个人化医学在肿瘤学中的应用的增加,预计市场将出现显著增长。 此外,基因组学的进步和辅助诊断测试的提供正在帮助医生根据对个体患者肿瘤生物学的深刻了解提供定制的治疗计划。 不断研究分子一级对癌症的认识,将进一步推动采用精确肿瘤学做法。

市场驱动力 -- -- 全球癌症发病率上升

癌症的发病率在全世界迅速上升。 几年前,癌症被认为是发达国家的疾病,但现在它已成为全世界一个重大的公共卫生问题。 预期寿命延长、生活方式改变和饮食习惯等因素导致新癌症病例逐年稳步增加。 虽然许多高收入国家的癌症死亡率由于更好的诊断和治疗而有所下降或保持稳定,但发展中国家的负担是巨大的。 据世卫组织称,预计今后几十年全球癌症发病率将至少增加70%。 这种令人震惊的上升势必使保健系统和资源不堪重负,除非我们找到新的方法来准确诊断和有效治疗癌症患者。 精密肿瘤学旨在通过针对个别患者的肿瘤进行特制治疗来解决这一紧迫挑战. 它利用强大的分子测试技术分析每个癌症病例中存在的独特基因突变和生物标记. 根据这种详细的分子剖面分析,医生能够选择目标药物、免疫疗法或其他最能防治这种特定癌症的疗法。 与传统的 " 一刀切 " 治疗方法相比,这带来更高的效益和更好的结果。 随着全球癌症病例在未来数年里呈指数增长,特别是在资源有限的发展中国家,精确肿瘤学通过使每个病人在适当的时候得到正确的治疗而带来希望。 它的广泛采用可以帮助控制癌症护理的螺旋性成本,并显著改善人们的生活. 因此,癌症发病率急剧上升,既构成临床挑战,也构成经济挑战,而精密医学是完全能够应付的。

对肿瘤学中个性化医学的需求日益增加

病人和医疗界日益认识到个人化癌症护理的重要性。 常规治疗战略往往没有考虑到癌症患者之间差别很大的基本肿瘤生物学。 这导致治疗不一致,抗药性以及治疗失败或复发率高. 精密医学通过详细绘制每个癌症的分子指纹来弥补这一缺陷. 它帮助医生选择适合患者特殊疾病特征的最佳治疗组合. 这大大促进了结果,同时使病人免于不当治疗的毒性。 最近在临床上取得了几项精确肿瘤学的成功,提高了病人的期望。 癌症幸存者希望有同样的机会获得个性化的护理,而基因组学的洞察力今后可能为其他人提供这种机会.

同时,肿瘤学家承认精确工具在临床上对指导治疗决定的实用性. 全面的基因组特征分析有助于确定可采取行动的变异,并制订循证治疗计划。 它还揭示了潜在的毒品目标和抗药性机制,以预先规划反应措施。 随着更多生物标志驱动的试验在基因组改变和药物反应之间建立了很强的关联性,精密医学作为新的护理标准越来越突出. 付款人也认识到其价值,其形式是更高的响应率、扩大生存效益和成本效益潜力。 有了这些优势,在癌症管理方面对分子肿瘤分析和相应的定向疗法的需求正在各利益相关群体之间加速。 研究人员和生物制药公司不断努力改进精密技术和治疗办法,以满足这种日益增长的需要。

市场挑战----精密药品成本高

全球肿瘤精密医学市场面临的主要挑战之一是精密医学成本高昂。 发展精密药物需要广泛的研究和临床试验,以了解癌症的分子机制以及定向疗法如何影响具体的突变. 这种研究和开发过程对制药公司来说非常昂贵。 精密药品一旦开发,还需要病人和付款人支付高价,以收回毒品制造者的投资。 新开发的基因疗法和个性化药物的成本通常为每门治疗课程数十万美元。 这不仅给病人带来了沉重的财政负担,而且对保健系统的可持续性提出了挑战。 负担能力问题可能限制精准疗法的采用和广泛采用,特别是在中低收入国家。 制药公司和监管机构需要合作,使这些拯救生命的治疗更负担得起,并让全球所有癌症患者更容易获得。

市场机会 -- -- 基因组分析的技术进步

基因组特征分析和分子诊断技术的不断增长的技术进步为全球肿瘤精密医学市场的发展提供了重要机会。 早期的基因组分析需要肿瘤活检样本,但新的非侵入性或液态活检技术正在通过从简单的血液抽取分析循环肿瘤DNA来进行早期癌症检测。 这改善了基因组测试的可获性。 继续降低基因组测序成本,同时进行人工智能和大数据分析,有助于建立全面的癌症基因组数据库。 精密肿瘤学公司可以利用这种基因组学的洞察力和临床试验数据来识别更多的目标突变和生物标志特征. 更精确的基因组特征分析有助于向正确的患者群体提供正确的治疗. 日益将基因组数据纳入癌症护理途径,将加快模式向个性化护理方法的转变。 这为精密药品制造商带来了有利可图的前景。

By Type of Cancer - Rising Prevalence of Risk Factors Drives Bladder Cancer Segment Growth

In terms of By Type of Cancer, Bladder Cancer contributes the highest share of the market owing to the rising prevalence of associated risk factors. Bladder cancer occurs when abnormal cells grow uncontrollably in the urinary bladder. Some of the major risk factors that are driving higher incidence of bladder cancer include increasing tobacco consumption, occupational chemical exposure, aging population and history of bladder infections.

Tobacco usage is the primary risk factor for bladder cancer with smoking accounting for over 50% of new cases. Countries with higher smoking rates consequently report greater bladder cancer burden. With limited progress on reducing smoking rates globally, bladder cancer cases linked to tobacco are projected to rise substantially.

Moreover, prolonged exposure to occupational or environmental chemicals like aromatic amines, polycyclic aromatic hydrocarbons are known bladder carcinogens. Workers involved in rubber, leather, textile and paint industries have elevated risk. Rapid industrialization and lack of stringent safety standards in emerging markets have augmented chemical exposure over the years.

An aging population structure is another prominent driver. Bladder cancer risk multiplies with advancing age and median age at diagnosis is 73 years. With life expectancy increasing worldwide, prevalence demographics have shifted towards geriatric groups who are more susceptible.

History of urinary tract infections or stones is also associated with higher odds of bladder cancer. Growing prevalence of diabetes and obesity, both of which predispose to urinary issues, have indirectly contributed to the bladder cancer segment growth.

Given the infiltrative nature of disease, advanced bladder tumors often require multiple treatment lines including chemotherapy, immunotherapy and surgery. Rising patient volumes therefore translate to increased demand for precision medicine solutions tailored for bladder cancer subtypes and stages. This has been a major factor propelling the bladder cancer segment.

By routes of administration - Oral Route Dominates Due to Ease of Administration

Among routes of administration, the oral segment holds the largest share in the global oncology precision medicine market. This is mainly attributed to enhanced patient acceptability for oral drugs relative to intravenous alternatives.

Oral therapy offers less invasive dosing without the need for hospital visits or skilled health professionals. It allows for self-administration at home, improving compliance and convenience significantly. This assumes greater importance in aging populations and developing countries with limited healthcare infrastructure.

Moreover, oral drugs are more cost effective in the long run versus frequent infusions requiring hospital resources. Out of pocket costs for patients are lower with oral medicine leading to better accessibility and affordability.

From the perspective of pharmaceutical firms as well, oral formulations present higher profit margins and preferential reimbursement policies compared to injectable drugs. Manufacturing, distribution and storage are also less complex for oral pills. This makes investments in oral precision oncology solutions commercially attractive.

The oral route is well-suited for chronic therapies like targeted therapies and immunotherapies which form the cornerstone of precision cancer treatment. Sustained availability of drug in the body from oral dosing matches the goals of these regimens better than intermittent intravenous deliveries.

Given these patient, healthcare system and industry related benefits, a majority of new precision medicine product launches are increasingly via the oral route fuelling its market dominance over time. Emergence of novel formulations improving oral bioavailability further reinforces oral administration.

By molecule type - Inexpensiveness Drives Small Molecules Adoption

Among molecule types, small molecules account for the highest share in the global oncology precision medicine sector owing to their relative cost-effectiveness compared to biologics.

Being synthesized chemically, small molecule targeted therapies enjoy lower production costs without expensive bioprocessing requirements. This allows for more competitive pricing and greater affordability for stretched healthcare budgets worldwide.

Lower list prices in turn translate to wider insurance coverage and larger patient populations gaining access to precision cancer care. The inherent economics of small molecules positively impact their volume driven adoption across both developed and developing markets.

Additionally, most small molecules are orally bioavailable which links well to the preponderance of convenient oral administration highlighted earlier. This doubles their practical advantages over injectable biologics from both cost and dosing compliance viewpoints.

Generic versions of leading small molecules will also emerge earlier than complex biologics once initial patents expire, creating opportunities for more affordable biosimilars/generics. Such subsequent price decreases facilitate the continued dominance of small molecule targeted therapies.

Unlike injectable antibodies or other biologics requiring cold chain logistics, small molecule pills can be easily stored and transported globally. This expands addressable volumes for pharmaceutical companies by improving geographical reach.

在全球肿瘤精密医学市场运营的主要角色包括安根,BioNTech,Gilead Sciences,Merck & Co.,Illumina, Foundation Medicine, Guardant Health, Caris Life Science, Exact Sciences, Myriad Genetics, Thermo Fisher Science, Invitae, 基因组健康,Syapse和Tempus.